Shashank Radadiya, MD
Rheumatology · Kansas City, KSNPI 1306887161
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,700 of the $73,761 with a category attached, or 78.2%. AbbVie accounts for 91.1% of it on its own, with 27 other manufacturers making up the rest. Among rheumatology clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 710 payments — averaging $103.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$67K
- Amgen$4K
- Lilly USA, LLC$413
- Novartis$375
- Johnson & Johnson$324
- Pfizer$319
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$57,70078%
- Travel & lodging$4,3986%
- Food & beverage$11,40315%
- Education$2600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 279 | $67,161 |
| Amgen(2 entities) | 233 | $3,520 |
| Lilly USA, LLC | 32 | $413 |
| Novartis | 18 | $375 |
| Johnson & Johnson(2 entities) | 12 | $324 |
| Pfizer | 50 | $319 |
| E.r. Squibb & Sons, L.L.C. | 21 | $253 |
| AstraZeneca(2 entities) | 7 | $196 |
| Bayer | 5 | $182 |
| Boehringer Ingelheim | 8 | $178 |
| UCB, Inc. | 8 | $148 |
| Novo Nordisk | 5 | $108 |
| GSK | 6 | $107 |
| Mallinckrodt Hospital Products Inc. | 2 | $87 |
| Fresenius Kabi USA, LLC | 3 | $67 |
| Regeneron Healthcare Solutions, Inc. | 4 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $47 |
| Organon | 2 | $36 |
| Sanofi | 2 | $31 |
| Xeris Pharmaceuticals, Inc. | 2 | $29 |
| Dexcom, Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Valeritas, Inc. | 1 | $17 |
| Abbott | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$73,761 in reported general payments places this provider in the 95th percentile of 49 rheumatology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 110 | $904,500 |
| RinvoqUpadacitinib | 93 | $660,438 |
| Humira(Cf) PenAdalimumab | 64 | $551,509 |
| EnbrelEtanercept | 57 | $466,108 |
| Xeljanz XrTofacitinib Citrate | 54 | $345,894 |
| OtezlaApremilast | 29 | $143,303 |
| Humira(Cf)Adalimumab | 12 | $96,695 |
| XeljanzTofacitinib Citrate | 11 | $58,788 |
| Actemra ActpenTocilizumab | 12 | $50,223 |
| Hydroxychloroquine Sulfate | 726 | $19,358 |
| MethotrexateMethotrexate Sodium | 566 | $9,166 |
| Leflunomide | 84 | $3,807 |
| Gabapentin | 168 | $3,285 |
| Tramadol Hcl | 219 | $3,249 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 67 | $2,972 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $67,161 | $757,134105 claims |
| AmgenEnbrel, Otezla | $3,520 | $609,41286 claims |
| PfizerXeljanz | $319 | $58,78811 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $13 | $1,54426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 rheumatology providers in Kansas.
Other rheumatology in Kansas City
- Kavish SinghKansas City$2K
- Paul SchmidtKansas City$1K
- Kasey McDonaldKansas City$740
- Rashmi ThimmapuramKansas City$471
- Michael DennisKansas City$452
- Herbert LindsleyKansas City$152
- Sarah Abi DoumethKansas City$103
- Amy MarkeyKansas City$84
- Amrita BathKansas City$28
- Sarah IfteqarKansas City$27
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.